Yourgene Health PLC Director's dealing (8441A)

TIDMYGEN

RNS Number : 8441A

Yourgene Health PLC

03 June 2019

Yourgene Health plc

("Yourgene Health" or the "Company")

Director's Dealing

Manchester, UK - 3 June 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces that it was notified on 31 May 2019 that Adam Reynolds, Chairman and a director of the Company, purchased 900,000 ordinary shares of 0.10p each in the Company on 31 May 2019 at a price of 11 pence per ordinary share.

Following the purchase, Mr Reynolds holds 6,349,656 ordinary shares in the Company representing 1.1% of the Company's issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                           Mr Adam Reynolds 
     -----------------------------  --------------------------------- 
 2    Reason for the notification 
     ---------------------------------------------------------------- 
 a)   Position/status                Non-Executive Chairman / PDMR 
     -----------------------------  --------------------------------- 
 b)   Initial notification           Initial 
       /Amendment 
     -----------------------------  --------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------- 
 a)   Name                           Yourgene Health plc 
     -----------------------------  --------------------------------- 
 b)   LEI                            213800UUIT8BZE7QEH33 
     -----------------------------  --------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ---------------------------------------------------------------- 
 a)   Description of the             Ordinary shares of 0.10p each 
       financial instrument, 
       type of instrument 
                                      ISIN: GB00BN31ZD89 
       Identification code 
     -----------------------------  --------------------------------- 
 b)   Nature of the transaction      Direct purchase of shares 
     -----------------------------  --------------------------------- 
 c)   Price(s) and volume(s)           Price(s)   Volume(s) 
                                        11p        900,000 
                                                  ---------- 
     -----------------------------  --------------------------------- 
 d)   Aggregated information         N/A 
       - Aggregated volume 
       - Price 
     -----------------------------  --------------------------------- 
 e)   Date of the transaction        31 May 2019 
     -----------------------------  --------------------------------- 
 f)   Place of the transaction       London Stock Exchange 
     -----------------------------  --------------------------------- 
 
 
For more information, please contact: 
Yourgene Health plc                                 Tel: +44 (0)161 
 Lyn Rees, Chief Executive Officer                   667 1053 
 Barry Hextall, Chief Financial Officer 
 Joanne Cross, Head of Marketing 
 [e-mail] 
Cairn Financial Advisers LLP (Nomad)                Tel: [phone] 
 Liam Murray / James Caithie / Ludovico Lazzaretti   0880 
Stifel Nicolaus Europe Limited (Corporate Broker)   Tel: [phone] 
 Nicholas Moore / Matthew Blawat / Ben Maddison      7600 
Vigo Communications (PR)                            Tel: [phone] 
 Ben Simons / Fiona Henson / Antonia Pollock         0238 
 [e-mail] 
 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHGMGGVRMLGLZG

(END) Dow Jones Newswires

June 03, 2019 02:01 ET (06:01 GMT)